Akt1 Enhances CA916798 Expression through mTOR Pathway-Reference-Cited by-全球学者库

Akt1 Enhances CA916798 Expression through mTOR Pathway

Published:2013-05-08 Issue:5 Volume:8 Page:e62327
ISSN:1932-6203
Container-title:PLoS ONE
language:en
Short-container-title:PLoS ONE

Author:

Wang Yu-Liang,Zhu Bing-Jing,Qi Zhan-Zhong,Wang Hai-Jing,Zhou Xiang-Dong

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference35 articles.

1. Cancer statistics, 2012;R Siegel;CA Cancer J Clin,2012

2. Koberle B, Tomicic MT, Usanova S, Kaina B (2010) Cisplatin resistance: Preclinical findings and clinical implications. Biochim Biophys Acta.

3. Resistance mechanisms to cancer chemotherapy;KM Redmond;Frontiers in bioscience : a journal and virtual library,2008

4. Drug resistance and its significance for treatment decisions in non-small-cell lung cancer;E Tsvetkova;Current oncology (Toronto, Ont ),2012

5. Ma PC (2012) Personalized targeted therapy in advanced non-small cell lung cancer. Cleveland Clinic journal of medicine 79 Electronic Suppl 1: eS56–60.

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CA916798 predicts poor prognosis and promotes Gefitinib resistance for lung adenocarcinoma;BMC Cancer;2023-03-23

2. Effects of perfluorooctanoic acid on endoplasmic reticulum stress and lipid metabolism-related genes in human pancreatic cells;Environmental Toxicology and Pharmacology;2023-03

3. Evaluation of the epigenetic alterations and gene expression levels of HepG2 cells exposed to zearalenone and α-zearalenol;Toxicology Letters;2020-06

4. CA916798 gene expression is associated with multidrug resistance and predicts progression‑free survival in patients with lung cancer;Oncology Letters;2019-06-04

5. Bisdemethoxycurcumin sensitizes cisplatin-resistant lung cancer cells to chemotherapy by inhibition of CA916798 and PI3K/AKT signaling;Apoptosis;2017-07-04